Alvimopan, a peripherally acting μ-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: Economic analysis of a phase 4 randomized, controlled trial

Teresa L. Kauf, Robert S. Svatek, Gilad Amiel, Timothy L. Beard, Sam S. Chang, Amr Fergany, R. Jeffrey Karnes, Michael Koch, Jerome O'Hara, Cheryl T. Lee, Wade J. Sexton, Joel W. Slaton, Gary D. Steinberg, Shandra S. Wilson, Lee Techner, Carolyn Martin, Jessica Moreno, Ashish M. Kamat

Research output: Contribution to journalArticle

43 Scopus citations

Abstract

Purpose We evaluated the effect of alvimopan treatment vs placebo on health care utilization and costs related to gastrointestinal recovery in patients treated with radical cystectomy in a randomized, phase 4 clinical trial. Materials and Methods Resource utilization data were prospectively collected and evaluated by cost consequence analysis. Hospital costs were estimated from 2012 Medicare reimbursement rates and medication wholesale acquisition costs. Differences in base case mean costs between the study cohorts for total postoperative ileus related costs (hospital days, study drug, nasogastric tubes, postoperative ileus related concomitant medication and postoperative ileus related readmissions) and total combined costs (postoperative ileus related, laboratory, electrocardiograms, nonpostoperative ileus related concomitant medication and nonpostoperative ileus related readmission) were evaluated by probabilistic sensitivity analysis using a bootstrap approach. Results Mean hospital stay was 2.63 days shorter for alvimopan than placebo (mean ± SD 8.44 ± 3.05 vs 11.07 ± 8.23 days, p = 0.005). Use of medications or interventions likely intended to diagnose or manage postoperative ileus was lower for alvimopan than for placebo, eg total parenteral nutrition 10% vs 25% (p = 0.001). Postoperative ileus related health care costs were $2,340 lower for alvimopan and mean total combined costs were decreased by $2,640 per patient for alvimopan vs placebo. Analysis using a 10,000-iteration bootstrap approach showed that the mean difference in postoperative ileus related costs (p = 0.04) but not total combined costs (p = 0.068) was significantly lower for alvimopan than for placebo. Conclusions In patients treated with radical cystectomy alvimopan decreased hospitalization cost by reducing the health care services associated with postoperative ileus and decreasing the hospital stay.

Original languageEnglish (US)
Pages (from-to)1721-1727
Number of pages7
JournalJournal of Urology
Volume191
Issue number6
DOIs
StatePublished - Jun 2014

Keywords

  • cost-benefit analysis
  • gastrointestinal tract
  • ileus
  • postoperative complications
  • urinary bladder

ASJC Scopus subject areas

  • Urology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Alvimopan, a peripherally acting μ-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: Economic analysis of a phase 4 randomized, controlled trial'. Together they form a unique fingerprint.

  • Cite this

    Kauf, T. L., Svatek, R. S., Amiel, G., Beard, T. L., Chang, S. S., Fergany, A., Karnes, R. J., Koch, M., O'Hara, J., Lee, C. T., Sexton, W. J., Slaton, J. W., Steinberg, G. D., Wilson, S. S., Techner, L., Martin, C., Moreno, J., & Kamat, A. M. (2014). Alvimopan, a peripherally acting μ-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: Economic analysis of a phase 4 randomized, controlled trial. Journal of Urology, 191(6), 1721-1727. https://doi.org/10.1016/j.juro.2013.12.015